Pruritus response and skin biomarkers of atopic dermatitis with crisaborole vs. vehicle in patients with mild-to-moderate atopic dermatitis

被引：0
|
作者：
Bissonnette, R. [1 ]
Guttman-Yassky, E. [2 ]
Werth, J. L. [3 ]
Zang, C. [3 ]
Cha, A. [4 ]
Vlahos, B. [3 ]
Myers, D. E. [3 ]
Nocka, K. H. [5 ]
Ports, W. C. [6 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA
[3] Pfizer Inc, Collegeville, PA USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Cambridge, MA USA
[6] Pfizer Inc, Groton, CT 06340 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P20
引用
收藏
页码：E104 / E104
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs
    Cao, Xue-chen
    Lu, Jia-wei
    Feng, Yi-fei
    Song, Le-bin
    Lu, Yan
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (07) : 4657 - 4662
  • [42] Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
    Luger, Thomas A.
    Hebert, Adelaide A.
    Zaenglein, Andrea L.
    Silverberg, Jonathan, I
    Tan, Huaming
    Ports, William C.
    Zielinski, Michael A.
    PEDIATRIC DRUGS, 2022, 24 (02) : 175 - 183
  • [43] CRISABOROLE OINTMENT PROVIDES EARLY RELIEF OF PRURITUS IN TWO PHASE 3 CLINICAL TRIALS IN PATIENTS WITH MILD OR MODERATE ATOPIC DERMATITIS
    Guttman-Yasky, Emma
    Yosipovitch, Gil
    Murrell, Dedee
    Ha-Nifin, Jon
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 1015 - 1016
  • [44] Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients with mild or moderate atopic dermatitis
    Guttman-Yassky, E.
    Yosipovitch, G.
    Murrell, D.
    Hanifin, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S194 - S194
  • [45] Patient impact and economic burden of mild-to-moderate atopic dermatitis
    Hebert, Adelaide A.
    Stingl, Georg
    Ho, LoAn K.
    Lynde, Charles
    Cappelleri, Joseph C.
    Tallman, Anna M.
    Zielinski, Michael A.
    Frajzyngier, Veronica
    Gerber, Robert A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (12) : 2177 - 2185
  • [46] Relationship between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole
    Staender, Sonja
    Yosipovitch, Gil
    Bushmakin, Andrew
    Cappelleri, Joseph
    Luger, Thomas
    Tom, Wynnis
    Ports, William
    Tallman, Anna
    Tan, Huaming
    Gerber, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB244 - AB244
  • [47] Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
    Valerie D. Callender
    Andrew F. Alexis
    Linda F. Stein Gold
    Mark G. Lebwohl
    Amy S. Paller
    Seemal R. Desai
    Huaming Tan
    William C. Ports
    Michael A. Zielinski
    Anna M. Tallman
    American Journal of Clinical Dermatology, 2019, 20 : 711 - 723
  • [48] THE ECONOMIC AND PATIENT BURDEN OF MILD-TO-MODERATE ATOPIC DERMATITIS IN PEDIATRIC PATIENTS IN SWEDEN
    Ortsater, G.
    Geale, K.
    Dun, Rieem A.
    Cappelleri, J. C.
    Cha, A.
    Romero, W.
    Neary, M. P.
    VALUE IN HEALTH, 2019, 22 : S639 - S639
  • [49] Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
    Callender, Valerie D.
    Alexis, Andrew F.
    Gold, Linda F. Stein
    Lebwohl, Mark G.
    Paller, Amy S.
    Desai, Seemal R.
    Tan, Huaming
    Ports, William C.
    Zielinski, Michael A.
    Tallman, Anna M.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (05) : 711 - 723
  • [50] Efficacy and safety trends with continuous long-term use of crisaborole ointment 2% in patients with mild-to-moderate atopic dermatitis
    Lebwohl, M. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E100 - E101
12345